Cargando…

Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis

BACKGROUND AND OBJECTIVES: The anti-CD20 antibody ofatumumab is an efficacious therapy for multiple sclerosis (MS) through depletion of B cells. The purpose of this study was to examine the derivative effects of B cell depletion on the peripheral immune system and a direct treatment effect on T cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Essen, Marina Rode, Hansen, Rikke Holm, Højgaard, Camilla, Ammitzbøll, Cecilie, Wiendl, Heinz, Sellebjerg, Finn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272791/ https://www.ncbi.nlm.nih.gov/pubmed/35672145 http://dx.doi.org/10.1212/NXI.0000000000200004

Ejemplares similares

Intrathecal CD8(+)CD20(+) T Cells in Primary Progressive Multiple Sclerosis
por: von Essen, Marina Rode, et al.
Publicado: (2023)

Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control
por: von Essen, Marina Rode, et al.
Publicado: (2023)

Increased Intrathecal Activity of Follicular Helper T Cells in Patients With Relapsing-Remitting Multiple Sclerosis
por: Holm Hansen, Rikke, et al.
Publicado: (2022)

Progressive multiple sclerosis, cognitive function, and quality of life
por: Højsgaard Chow, Helene, et al.
Publicado: (2018)

Relationship between Multiple Sclerosis-Associated IL2RA Risk Allele Variants and Circulating T Cell Phenotypes in Healthy Genotype-Selected Controls
por: Buhelt, Sophie, et al.
Publicado: (2019)

Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial
por: Højsgaard Chow, Helene, et al.
Publicado: (2021)

IL2RA Methylation and Gene Expression in Relation to the Multiple Sclerosis-Associated Gene Variant rs2104286 and Soluble IL-2Rα in CD8(+) T Cells
por: Buhelt, Sophie, et al.
Publicado: (2021)

Inflammatory vaginitis associated with long-term rituximab treatment in a patient with multiple sclerosis
por: Filikci, Zuhal, et al.
Publicado: (2022)

IL-6, IL-12, and IL-23 STAT-Pathway Genetic Risk and Responsiveness of Lymphocytes in Patients with Multiple Sclerosis
por: von Essen, Marina R., et al.
Publicado: (2019)

Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
por: Kang, Connie, et al.
Publicado: (2021)

Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
por: Hauser, Stephen L, et al.
Publicado: (2022)

Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
por: Kang, Connie, et al.
Publicado: (2021)

The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
por: Hauser, Stephen L., et al.
Publicado: (2023)

Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis
por: Yu, Huixin, et al.
Publicado: (2022)

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
por: Bar-Or, Amit, et al.
Publicado: (2018)

Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
por: Florou, Despoina, et al.
Publicado: (2020)

Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis
por: Kramer, John, et al.
Publicado: (2023)

Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis
por: Carrión, Belinda, et al.
Publicado: (2021)

Impfungen unter Ofatumumab gelingen
por: Facharztmagazine, Redaktion
Publicado: (2023)

COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
por: Cross, Anne H., et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
por: Baharnoori, Moogeh, et al.
Publicado: (2022)

Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada
por: Bhan, Virender, et al.
Publicado: (2023)

Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab
por: Craner, Matthew, et al.
Publicado: (2022)

Gut–CNS-Axis as Possibility to Modulate Inflammatory Disease Activity—Implications for Multiple Sclerosis
por: Fleck, Ann-Katrin, et al.
Publicado: (2017)

Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study
por: Bar-Or, Amit, et al.
Publicado: (2021)

Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab
por: Adamec, Ivan, et al.
Publicado: (2022)

Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
por: Cross, Anne H., et al.
Publicado: (2022)

Remission of idiopathic retroperitoneal fibrosis by ofatumumab as a disease-modifying therapy for multiple sclerosis
por: Hanazono, Akira, et al.
Publicado: (2022)

Ofatumumab treatment in lupus nephritis patients
por: Haarhaus, Malena Loberg, et al.
Publicado: (2016)

Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease
por: Vinther-Jensen, Tua, et al.
Publicado: (2016)

Pulsed immune reconstitution therapy in multiple sclerosis
por: Sorensen, Per Soelberg, et al.
Publicado: (2019)

Role of ofatumumab in treatment of chronic lymphocytic leukemia
por: Veliz, Marays, et al.
Publicado: (2011)

Refractory pemphigus vulgaris successfully treated with ofatumumab
por: Klufas, Daniel M., et al.
Publicado: (2020)

Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination
por: Faissner, Simon, et al.
Publicado: (2022)

Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension
por: Hauser, Stephen L, et al.
Publicado: (2023)

Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis
por: Börnsen, Lars, et al.
Publicado: (2012)

The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia
por: Nabhan, Chadi, et al.
Publicado: (2011)

Nutzen der frühzeitigen Behandlung mit Ofatumumab bestätigt
por: Linder, Isabelle
Publicado: (2022)

Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II
por: Gärtner, Jutta, et al.
Publicado: (2022)

What Do We Know So Far about Ofatumumab for Relapsing Multiple Sclerosis? A Meta-Analytical Study
por: Taj, Hafiza Munazza, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8v7jkr3bitv0dqq14mfjv8mj6v